1. Home
  2. USEA vs MRKR Comparison

USEA vs MRKR Comparison

Compare USEA & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Maritime Corporation

USEA

United Maritime Corporation

N/A

Current Price

$2.49

Market Cap

21.7M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$0.90

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USEA
MRKR
Founded
2004
1999
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
19.5M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
USEA
MRKR
Price
$2.49
$0.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.87
AVG Volume (30 Days)
79.8K
★ 169.0K
Earning Date
11-13-2026
11-12-2026
Dividend Yield
★ 8.98%
N/A
EPS Growth
N/A
★ 33.61
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.16
$19.61
Revenue Next Year
N/A
$375.85
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.42
$0.84
52 Week High
$3.20
$2.46

Technical Indicators

Market Signals
Indicator
USEA
MRKR
Relative Strength Index (RSI) 41.57 40.24
Support Level $2.46 $0.88
Resistance Level $2.63 $1.32
Average True Range (ATR) 0.10 0.12
MACD 0.01 -0.00
Stochastic Oscillator 35.98 9.27

Price Performance

Historical Comparison
USEA
MRKR

About USEA United Maritime Corporation

United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: